22-Oxovincaleukoblastine
22-Oxovincaleukoblastine Brand names, 22-Oxovincaleukoblastine Analogs
- 22-Oxovincaleukoblastine
- Indole alkaloid
- LCR
- Leurocristine
- Onco TCS
- Oncovin
- Oncovin (1:1 sulfate salt)
- VCR
- VIN
- Vincaleukoblastine, 22-oxo-
- Vincasar (1:1 sulfate salt)
- Vincasar PFS
- Vincrex
- Vincrex (1:1 sulfate salt)
- Vincristina [DCIT]
- Vincristine Sulfate
- Vincristine Sulfate PFS
- Vincristinum [INN-Latin]
- Vincrstine
- Vincrystine
- Vinkristin
- Z-D-Val-Lys(Z)-OH
22-Oxovincaleukoblastine Brand Names Mixture
- No information avaliable
22-Oxovincaleukoblastine Chemical_Formula
C46H56N4O10
22-Oxovincaleukoblastine RX_link
http://www.rxlist.com/cgi/generic3/vincristine.htm
22-Oxovincaleukoblastine fda sheet
22-Oxovincaleukoblastine msds (material safety sheet)
22-Oxovincaleukoblastine Synthesis Reference
No information avaliable
22-Oxovincaleukoblastine Molecular Weight
824.958 g/mol
22-Oxovincaleukoblastine Melting Point
220 oC
22-Oxovincaleukoblastine H2O Solubility
No information avaliable
22-Oxovincaleukoblastine State
Solid
22-Oxovincaleukoblastine LogP
4.918
22-Oxovincaleukoblastine Dosage Forms
Liquid; Solution
22-Oxovincaleukoblastine Indication
For treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia, acute panmyelosis
22-Oxovincaleukoblastine Pharmacology
Vincristine is a vinca alkaloid antineoplastic agent used as a treatment for various cancers including breast cancer, Hodgkin's disease, Kaposi's sarcoma, and testicular cancer. The vinca alkaloids are structurally similar compounds comprised of 2 multiringed units, vindoline and catharanthine. The vinca alkaloids have become clinically useful since the discovery of their antitumour properties in 1959. Initially, extracts of the periwinkle plant (Catharanthus roseus) were investigated because of putative hypoglycemic properties, but were noted to cause marrow suppression in rats and antileukemic effects in vitro. Vincristine binds to the microtubular proteins of the mitotic spindle, leading to crystallization of the microtubule and mitotic arrest or cell death. Vincristine has some immunosuppressant effect. The vinca alkaloids are considered to be cell cycle phase-specific.
22-Oxovincaleukoblastine Absorption
No information avaliable
22-Oxovincaleukoblastine side effects and Toxicity
IVN-RAT LD50 1300 mg/kg; IPR-MUS LD50 5.2 mg/kg
22-Oxovincaleukoblastine Patient Information
PATIENT INFORMATION
Follow the links
http://www.rxlist.com/cgi/generic3/vincristine_wcp.htm
http://www.drugs.com/cons/Vincristine.html
Follow the links
http://www.rxlist.com/cgi/generic3/vincristine_wcp.htm
http://www.drugs.com/cons/Vincristine.html
22-Oxovincaleukoblastine Organisms Affected
Humans and other mammals
